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PENILAIAN BERKENAAN PENYAKIT BUAH PINGGANG 
KRONIK DAN CORAK PRESKRIPSI UBAT-UBATAN DI 
SEBUAH PUSAT RAWATAN TERTIARI DI MALAYSIA 
ABSTRAK 
 
Penyakit buah pinggang kronik merupakan masalah perubatan sejagat yang semakin 
meningkat, ia menjejaskan sosioekonomi keluarga pesakit dan juga negara, maklumat 
berkenaan punca penyakit tersebut dan corak preskripsi ubat-ubatan yang diperlukan 
untuk memperbaiki hasil klinikal jarang didapati di Malaysia. Oleh yang demikian 
kajian ini bertujuan untuk menilai punca-punca penyakit buah pinggang kronik dan 
ubat-uabatn yang digunakan oleh rakyat Malaysian yang mengalami penyakit buah 
pinggang kronik. Kajian retrospektif, keratan rentas ini telah dilaksanakan ke atas 
pesakit dewasa yang mengalami penyakit buah pinggang kronik, yang mendapat 
rawatan di Hospital Universiti Sains Malaysia, daripada 1 Januari 2009 hingga ke 31 
Disember 2013. Data pesakit berkenaan dengan sosiodemografik, laporan makmal, 
punca-punca penyakit, peringkat penyakit buah pinggang kronik dan jenis ubat-ubatan 
telah dikumpulkan. Ubat-ubatan tersebut telah diklasifikasikan berdasarkan 
“Anatomical Therapeutic Chemical Classification” seperti yang telah dicadangkan 
oleh Pertubuhan Kesihatan Sedunia. Perbandingan telah dilakukan di anatara 
kumpulan umur (bawah 50 tahun atau lebih 50 tahun), jantina, status diabetik dan 
peringkat penyakit buah pinggang kronik. Sejumlah 851 pesakit telah dimasukkan 
dengan nisbah antara lelaki ke perempuan pada 1.75:1.00 dengan purata umur 61.18  
13.37 tahun. Penyakit buah pinggang kronik peringkat 5 meliputi seramai 333 
(39.1%) kes, manakala peringkat 4, 3b, 3a dan 2 kes adalah sebanyak 240 (28.2%), 
186 (21.9%), 74 (.8.7%) dan 18 (2.1%) masing-masing. Berdasarkan sampel populasi, 
diabetic nefropati (DN) (44.9%) merupakan punca utama penyakit buah pinggang 
kronik, diikuti hipertensi (24.2%) dan obstruktif uropati (9.2%). Punca yang tidak 
 xiii 
 
diketahui meliputi 9.4% daripada kes-kes. Perbezaan diantara insiden penyakit buah 
pinggang kronik disebabkan oleh diabetik nepfropati, hipertensi, glomerulonefritis, 
pesakit yang berumur di bawah 50 tahun dan pesakit melebihi 50 tahun mempunyai 
nilai statistik yang signifikan (p = 0.008, p<0.001 dan p < 0.001, masing-masing). 
Pesakit-pesakit telah diberikan pelbagai jenis preskripsi iaitu 12.10  4.68 jenis ubat-
ubatan. Lima kumpulan ubat-ubatan teratas adalah ubat-ubatan anti-lipid, “calcium 
channel blockers”, “antiplatelet”, “diuretik” dan ubat-ubatan untuk masalah 
ketidakseimbanagn asid. Penggunaan suboptimal beberapa kumpulan ubat-ubatan 
adalah agak ketara. Umur pesakit dan jantina tidak mempengaruhi jumlah ubat-ubatan 
yang digunakan (p = 0.09 dan p = 0.40 masing-masing). Pesakit diabetes telah 
diberikan preskripsi ubat-ubatan yang lebih berbanding pesakit lain (13.96 ± 4.78 vs 
10.71 ± 3.60 p = 0.001).  Tambahan lagi, jumlah preskripsi ubat-ubatan meningkat 
secara sangat signifikan dengan penurunan fungsi buah pinggang mengikut turutan 
(penyakit buah pinggang peringkat 2 dan 3a < peringkat 3b< peringkat 4 < peringkat 
5 predialisis < peringkat 5 sedang menjalani dialysis). Keputusan kajian ini 
menunjukkan diabetik nefropati  merupakan punca utama penyakit buah pinggang 
kronik diikuti oleh penyakit darah tinggi. Kajian ini juga turut menunjukkan 
penggunaan ubat-ubatan dalam kalangan pesakit buah pinggang kronik di Malaysia. 
Penggunaan sesetengah kumpulan ubatan secara suboptimal agak ketara dan usaha 
yang instruktif ke arah ini akan memberikan hasil yang lebih baik. 
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EVALUATION OF CHRONIC KIDNEY DISEASE AND 
MEDICATION PRESCRIBING PATTERNS IN A SINGLE 
TERTIARY CARE CENTER IN MALAYSIA 
ABSTRACT 
 
Chronic kidney disease (CKD) is an escalating medical problem worldwide, effecting 
socioeconomic conditions of patient’s family and country, and information about its 
etiologies and medication prescribing patterns, needed to improve a better clinical 
outcome, is sparse in Malaysia. Therefore, this study is intended to evaluate the 
etiologies of CKD and medication use in Malaysian patients suffering from CKD. A 
retrospective, cross-sectional study was conducted on adult CKD patients, receiving 
treatment at Hospital Universiti Sains Malaysia, Kelantan, Malaysia from 1st January 
2009 to 31st December 2013. Data regarding patient socio-demographics, laboratory 
investigations, etiology, stage of CKD and medications were collected. Individual 
drugs were classified according to the Anatomical Therapeutic Chemical 
Classification as recommended by the World Health Organization (WHO). 
Comparison was made between age groups (≤ 50 or > 50 years), gender, diabetic 
status and CKD stages. A total of 851 eligible cases were included with male to 
female ratio of 1.75: 1.00 and mean age of 61.18 ± 13.37 years. CKD stage 5 was 
accounted in 333 (39.1%) cases whereas stage 4, 3b, 3a and 2 cases were 240 
(28.2%), 186 (21.9%), 74 (8.7%) and 18 (2.1%), respectively. In the sample 
population, diabetic nephropathy (DN) (44.9%) was found to be the foremost etiology 
of CKD, followed by hypertension (HPT) (24.2%) and obstructive uropathy (OBS) 
(9.2%). Unknown etiology constituted 9.4% of our cases. The difference of incidence 
of CKD due to DN, HPT, GN, patients of age ≤ 50 years and patients of age > 50 
years was statistically significant (P = 0.008, P < 0.001 and P < 0.001, respectively). 
Patients were prescribed 12.10 ± 4.68 medications. The top five prescribed 
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medication groups were found to be lipid lowering agents, calcium channel blockers, 
antiplatelet agents, diuretics and drugs for acid related disorders. Underutilization of 
several classes of medications was apparent. Patient age and gender did not influence 
the number of medications used (P = 0.09 and P = 0.40, respectively). Diabetic 
patients were prescribed more drugs than patients without DM (13.96 ± 4.78 vs 10.71 
± 3.60 p = 0.001). Moreover, the number of prescribed medications significantly 
increased with declining renal function with a hierarchy (stage 2 and 3a < stage 3b < 
stage 4 < stage 5ND < stage 5D). The results of the present study indicate that 
diabetic nephropathy is the chief cause of CKD followed by hypertension. This study 
also provides an overview of medication use in a Malaysian CKD population. 
Underutilization of some medication classes is apparent and instructive efforts in this 
direction may ascertain better outcomes. 
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CHAPTER 1 
INTRODUCTION 
1.1 General Introduction 
Kidney disease can either be acute or chronic. Acute kidney injury is the reversible 
decline in kidney function whereas chronic kidney disease (CKD) or chronic renal 
disease is the progressive destruction of kidney mass through loss of nephrons and 
irreversible sclerosis over a period of months or years (Gooneratne et al., 2008).  
 
CKD is a major health problem across the globe (Levey et al., 2009) and attention 
paid towards CKD is attributable to five factors; escalating prevalence, enormous 
treatment cost, recent data tell-tale that overt disease (stage 3 to 5) is merely the tip of 
an iceberg of furtive disease (stage 1 to 2), its major involvement in increasing risk of 
cardiovascular events and discovery of effective measures to retard its progression 
(Barsoum, 2006).  
 
1.2 Definition and classification of chronic kidney disease 
1.2.1 Definition and criteria for chronic kidney disease  
CKD is defined by Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 
(2013) as “abnormalities in kidney structure or function, present for more than three 
months”. The diagnostic criteria for CKD are shown in Table 1.1. 
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Table 1.1: Criteria for chronic kidney disease (Presence of either of the following 
for > 3 months) 
Declined glomerular filtration rate  GFR < 60 ml/min/1.73m
2
 
Indicators of kidney damage  Albuminuria (albumin excretion 
rate ≥ 30 mg/24hours; albumin-
to-creatinine ratio ≥30/g) 
 Urine sediment (casts and tubular 
epithelial cells) anomalies 
 Electrolytes or other 
abnormalities due to tubular 
disorders 
 Structured deformities identified 
by renal imaging 
 Kidney transplantation history 
 
Adapted from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013); 
GFR-glomerular filtration rate 
 
1.2.2 Classification of chronic kidney disease 
As per KDIGO guidelines (2013), CKD should be classified according to 
etiology, glomerular filtration rate (GFR) and albuminuria. Etiology of CKD is 
based on the presence or absence of systemic disease and the location inside the 
kidney of the observed or presumed pathological-anatomic findings. 
Normotensive young adults have GFR of approximately 120-130 ml/min/1.73m
2 
body surface area and declines with the age (Stevens & Levey, 2004). 
Classification of CKD according to GFR is presented in Table 1.2. 
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Table 1.2: Stages of chronic kidney disease based on glomerular filtration 
rate 
Stage of CKD Description GFR  (ml/min/1.73m
2
) 
Stage 1 Kidney damage and 
normal or increased 
kidney function 
≥ 90 ml/min/1.73m2 
Stage 2 Kidney damage with mild 
decrease in kidney 
function 
60-89 ml/min/1.73m
2
 
Stage 3a Mild to moderate 
decrease in Kidney 
function 
45-59 ml/min/1.73m
2
 
Stage 3b Moderate to severe 
decline in Kidney 
function 
30-44 ml/min/1.73m
2
 
Stage 4 Severe decline in kidney 
function 
15-29 ml/min/1.73m
2
 
Stage 5 Kidney failure < 15 ml/min/1.73m
2
 
 
Adapted from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013); 
CKD-chronic kidney disease; GFR-glomerular filtration rate 
 
As described in Table 1.2, renal function continually decline from Stage 1 to stage 
5. In the early stages of CKD, kidneys are able to adapt to the injury and maintain 
the GFR by increasing intraglomerular pressure and filtration rate by the 
remaining nephrons called hyper-filtration. Due to this mechanism early stages of 
CKD are under-diagnosed. But in the long run, the increased intraglomerular 
pressure further damages the remaining nephrons leading to kidney failure 
manifested by proteinuria (Haynes & Winearls, 2010). The categories of 
albuminuria as per KDIGO criteria are shown Table 1.3. 
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Table 1.3: Albuminuria categories in chronic kidney disease 
Category Description Albumin excretion 
rate 
Albumin-to-
creatinine ratio 
A1 Normal to mild increase < 30 mg/24 hours < 30 mg/g 
A2 Moderate increase 30-300 mg/24 hours 30-300 mg/g 
A3 Severe increase > 300 mg/24 hours > 300 mg/g 
 
Adapted from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) 
 
1.3 Symptoms of chronic kidney disease 
CKD is considered as a silent disease because its symptoms are subtle. The symptoms 
typically develop in late stages of CKD and usually only when end-stage renal disease 
(ESRD) is impending (Haynes & Winearls, 2010). The clinical manifestations 
including vomiting, anorexia, itching and muscle cramps –if attributable to CKD- are 
the indication of prompt initiation of renal replacement therapy (RRT) (Haynes & 
Winearls, 2010). Moreover, CKD patients also complain of dyspnea, edema and 
oliguria (Ulasi & Ijoma, 2010) The symptoms of CKD like vomiting and diarrhea 
further lead to nausea, dehydration and loss of weight because of increased level of 
urea in the body (Manley et al., 2012). Abnormal heart rhythm and muscle paralysis 
commonly experienced by CKD sufferers due to hyperkalemia (Einhorn et al., 2009). 
Proteinuria as a result of hyper-filtration is also a sign of CKD (Haynes & Winearls, 
2010). 
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1.4 Estimation of renal function 
 
The best index to measure renal function is GFR (Lascano & Poggio, 2010). GFR is 
the product of mean filtration rate of each sole nephron multiplied by the total number 
of nephrons present in both kidneys (Floege, Jhonson, & Feehally, 2010). Normal 
GFR level is around 130 ml/min/1.73m
2
 for men and 120ml/min/1.73m
2
 for women, 
with significant difference amongst individuals based on age, gender, body mass, diet, 
physical activity, pharmacological therapy, and physiological states e.g. pregnancy 
(Floege et al., 2010).  The adult GFR can be computed by applying Cockcroft-Gault 
(CG) equation, Modification of Diet in Renal Disease (MDRD) study equation, 
Chronic kidney disease- Epidemiology (CKD-EPI) creatinine equation, CKD-EPI 
cystatin C equation and CKD-EPI creatinine-cystatin C equation. 
 
1.4.1 Cockcroft-Gault (CG) equation 
In 1973, CG equation was developed to predict the creatinine clearance (Ccr) from 
serum creatinine (Scr), age and body weight (Cockcroft & Gault, 1976). The CG 
formula is expressed below: 
Ccr = (140 – age) × weight (Kg) / 72 ×Scr [× 0.85 if female]   
 
1.4.2 Modification of Diet in Renal Disease (MDRD) study equation 
The MDRD study equation was developed in 1999 using data including Caucasian 
and African-American CKD patients with GFR from 5-90 ml/min/1.73m
2
 body 
surface area as stated under: 
 
MDRD eGFR = 186 × (Scr)
-1.154
 × (age)
-0.023
 [×0.742 if female] [× 1.21 if black] 
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The aforementioned equation only requires data of serum creatinine, age and gender 
(Levey et al., 2000). 
 
1.4.3 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine 
equation 
The MDRD study equation was developed in CKD population and its major 
limitations were imprecision and systematic underestimation of GFR at levels > 
60ml/min/1.73m
2
 (Stevens et al., 2007). Therefore, a more accurate equation named 
CKD-EPI creatinine equation was designed in 2009 (Levey et al., 2009). The CKD-
EPI equation is given below: 
 
eGFR = 141× min(Scr/k, 1)
α 
× max(Scr/k, 1)
-1.209 
× 0.993
Age
 [× 1.018 if female] [× 
1.159 if black] 
 
Where Scr is Serum creatinine (mg/dl); k is 0.7 for females and 0.9 for males; α is --
0.329 for females and -0.411 for males; min is minimum of Scr/k or 1; max is 
maximum of Scr/k or 1 
 
In the comparative performance of MDRD formula and CKD-EPI creatinine formula, 
the latter formula was proven to be more accurate (Stevens et al., 2010). Maisarah et 
al. (2014) conducted a cross-sectional study to compare the performance of CKD-EPI 
and MDRD equations in multiethnic Malaysian population attending University 
Malaya Medical Centre. They reported that for eGFR < 30 ml/min/1.73m
2
 and 30-59 
ml/min/1.73m
2
 both equations had similar bias (median difference compared with 
measured GFR) but for eGFR 60-89 ml/min/1.73m
2
, bias decreased from 12.3 
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(MDRD equation) to 7.3 ml/min/1.73m
2
 (CKD-EPI equation) (41% improvement). 
Furthermore, for eGFR > 90 ml/min/1.73m
2
, bias was decreased from 11.7 (MDRD 
equation) to 11.5 ml/min/1.73m
2
 (CKD-EPI equation). Therefore, they concluded that 
CKD-EPI equation was more accurate than MDRD equation in estimating GFR > 60 
ml/min/1.73m
2
. 
 
1.4.4 CKD-EPI cystatin C equation 
Serum cystatin C level alone -as a replacement for Scr in estimation of renal function- 
provided GFR estimates as accurate as Scr (Stevens et al., 2008). The CKD-EPI 
cystatin C equation is stated as: 
 
eGFR = 133 × min(SCysC/0.8, 1)
-0.499 
× max(SCysC/0.8, 1)
-1.328 
× 0.996
Age
 [× 0.932 if 
female] 
 
Where SCysC is Serum cystatin C; min is minimum of SCysC/0.8 or 1; max is 
maximum of SCysC/0.8 or 1 
 
1.4.5 CKD-EPI creatinine-cystatin C equation 
The equation comprising SCys C level in combination with Scr level, sex, age and 
race provided the supreme accurate GFR estimates (Stevens et al., 2008). The CKD-
EPI creatine-cystatin C equation is given below: 
 
eGFR = 135 × min(Scr/k, 1)
α
 × max(Scr/k, 1)
-0.601 
×  min(SCysC/0.8, 1)
-0.375 
× 
max(SCysC/0.8, 1)
-0.711 
× 0.995
Age
 [× 0.969 if female] [× 1.08 if black] 
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Whereby Scr is Serum creatinine (mg/dl); SCysC is Serum cystatin C (mg/l); k is 0.7 
for females and 0.9 for males; α is -0.248 for females and -0.207 for males; min(Scr/k , 
1) is minimum of Scr/k or 1; max(Scr/k, 1) is maximum of Scr/k or 1; min(SCysC/0.8, 
1) is minimum of SCysC/0.8 or 1; max(SCysC/0.8, 1) is maximum of SCysC/0.8 or 1 
 
1.5 Assessment of individuals with higher risk for chronic kidney disease 
The predictors of CKD are hypertension, diabetes mellitus, older age (≥ 60 years), 
urinary tract infections, systemic infections, auto-immune diseases, nephrotoxic 
agents, cardiovascular disease (CVD), kidney stone, kidney cysts, hyperlipidemia, 
smoking, obesity and higher consumption of alcohol (Levey et al., 2003; Yamagata et 
al., 2007). Individuals with aforesaid risk factors of CKD should be assessed and 
managed to impede the progression of kidney damage.  
 
1.6 Assessment of proteinuria 
Normal kidneys excrete a very minor amount of protein but a persistent higher level 
of albumin excretion or ACR ≥ 30mg/g is an indicator of kidney damage (Kidney 
Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013). The 
kidney damage is linked with co-existing illnesses such as diabetes, hypertension and 
glomerular disease whereas the elevation in the excretion of low-molecular weight 
globulins is the indicator of tubolointerstitial disease (Levey et al., 2003). 
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1.7 Epidemiology of chronic kidney disease 
1.7.1 Prevalence of chronic kidney disease 
The prevalence of CKD varies from country to country. The median prevalence of 
CKD in individuals aged ≥ 30 years old was 7.2% whereas its prevalence in persons 
aged ≥ 64 years old ranged from 23.4-35.8% (Zhang & Rothenbacher, 2008). The 
prevalence of CKD was 15.6% and 8.5% in US and Mexico, respectively (Brown et 
al., 2003; Coresh et al., 2003). In another study from US, the estimated prevalence of 
CKD in non-institutionalized population was 4.5% (by MDRD equation) and 7.0% 
(by CG equation) (Coresh et al., 2005). In Canada, the estimated prevalence of CKD 
(participants from community-dwelling elderly in Calgary Health Region, aged ≥ 66 
years) was 35.4% (Hemmelgarn et al., 2006). 
 
The prevalence of CKD in European countries was 4.7% in Norway (Hallan et al., 
2006), 6.4% in Italy (Cirillo et al., 2006), 8.1% in Switzerland (Nitsch et al., 2006), 
35.8% in Finland (Wasen et al., 2004) and 5.1% in Spain (Otero et al., 2005).  The 
prevalence of CKD was 12.0% in Australia (McDonald et al., 2003).  
 
The prevalence of CKD in China, Thailand and Singapore was found to be 10.8%, 
17.5% and 6.6%, respectively (Ingsathit et al., 2010; Shankar et al., 2006; Zhang et 
al., 2008). In Japan, the prevalence rates of CKD stage 1, 2, 3, 4 and 5 in 2005 was 
0.2%, 1.7%, 10.4% and 0.2 %, respectively (Imai et al., 2009). 
 
According to population-based study conducted in West Malaysia (Hooi et al., 2013), 
the overall prevalence of CKD was 9.07% and the prevalence of CKD stage 1, 2, 3, 4 
and 5 was 4.16%, 2.05%, 2.26%, 0.24% and 0.36%, respectively. Furthermore, the 
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prevalence of end-stage renal disease (ESRD) Malaysian patients on dialysis had risen 
from 325 (year 2001) to 975 (year 2012) per million populations (pmp) (Lim et al., 
2013). The prevalence of CKD varied strongly with age, gender and ethnicity. 
Moreover, the prevalence estimates of CKD strongly depended on which equation 
was used for estimating the renal function (Zhang & Rothenbacher, 2008). 
 
1.7.2 Causes of chronic kidney disease 
Similar to the etiologies of acute kidney failure, CKD can also be categorized into 
pre-renal, renal and post-renal causes (Haynes & Winearls, 2010). The identifiable 
causes of CKD are shown in Table 1.4. 
Table 1.4: Identifiable etiologies of chronic kidney disease  
Etiologies Frequent Less frequent 
Pre-renal Renal arterial disease  
Renal Glomerular disease 
DN 
IgA nephropathy 
FSGS 
 
TIN 
PKD 
RN 
Glomerular disease 
Amyloidosis 
Vasculitis 
Hemolytic-uremia 
syndrome 
TIN 
Analgesic nephropathy 
Renal myeloma 
Post-renal Obstruction 
Prostatic 
Obstruction 
Retroperitoneal fibrosis 
 
Adapted from Haynes & Winearls (2010); DN-diabetic nephropathy; IgA-immunoglobulin A; FSGS-
focal segmental glomerulosclerosis; TIN-tubulointerstitial nephritis; RN-reflux nephropathy; PKD-
polycystic kidney disease 
 
 
As described in Table 1.4, glomerular diseases such as diabetic nephropathy, 
immunoglobulin A nephropathy (most common glomerulonephritis which causes 
CKD), focal segmental glomerulosclerosis, and tubulointerstitial nephritis are the 
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frequent renal causes of CKD. Moreover, renal arterial disease and obstruction due to 
prostate enlargement are the common pre-renal and post-renal etiologies of CKD 
 
1.8 Burden of chronic kidney disease 
1.8.1 Morbidity  
CKD is a growing public health problem across the world (Sakhuja & Kohli, 2006). 
The global annual growth rate of CKD is 8% (Alebiosu & Ayodele, 2005) while the 
annual dialysis growth rates are 6-8% per annum (Levin, 2003). Statistics from the 
United States advocated that for each patient with end-stage renal disease (ESRD), 
there are more than 200 with overt CKD (stage 3 or 4) and nearly 5000 with furtive 
disease (stage 1 or 2) (Barsoum, 2006).   
 
1.8.2 Mortality 
Disease of Genitourinary System is the 12
th
 and 17
th
 cause of mortality and disability 
worldwide, respectively (Schieppati & Remuzzi, 2005). In United States (US), kidney 
disease is the 8
th
 leading cause of mortality (Centers for Disease Control and 
Prevention, 2009).  
 
1.8.3 Economic burden 
The cost of medical care in US was 1.7 times greater in patients suffering from CKD 
stage 3 and 2.6 times greater in CKD stage 4 sufferers compared with controls (Smith 
et al., 2004). In US, the free-for-service Medicare expenditures per person per year 
were $87,945 and $71,630 for hemodialysis (HD) and peritoneal dialysis (PD) 
population, respectively (United States Renal Data System, 2013). The cost of 
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hemodialysis (HD) treatment in Malaysia ranged from RM79.61-475.79 (mean cost of 
RM169 per HD) while the mean cost of continuous ambulatory peritoneal dialysis 
(CAPD) was RM2186 per month (US $1 = RM 3.80) (Hooi et al., 2005). 
Furthermore, the cost of erythropoietin for HD and CAPD was RM4500 and RM2500 
per year, respectively. The abovementioned findings demonstrate that CKD has an 
enormous socio-economic burden on the healthcare system. 
 
1.9 Co-morbidities among chronic kidney patients 
Patients with CKD are known to suffer from various co-morbidities, complications 
and sequelae as a cause or consequence of renal disease (Bailie et al., 2005). The 
common co-morbidities of CKD include hypertension (HPT), diabetes mellitus (DM), 
cardiovascular disease (CVD), anemia, kidney stones, and disorders of mineral and 
bone metabolism. 
 
1.9.1 Hypertension 
Hypertension is the persistent elevated blood pressure (BP) > 140/90 mmHg 
(Chobanian et al., 2003). The classification of BP for adults 18 years and older is 
provided in Table 1.5. 
 
Table 1.5: Classification of blood pressure 
Classification Systolic blood pressure 
mm Hg 
Diastolic blood pressure 
mm Hg 
Normal < 120 < 80 
Prehypertension 120-139 80-89 
Hypertension ≥ 140 ≥ 90 
Stage 1 140-159 90-99 
Stage 2 ≥ 160 ≥ 100 
 
Adapted from Chobanian et al. (2003) 
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Approximately 80% of CKD patients have HPT and it is an imperative risk factor not 
only to renal disease progression towards end-stage renal failure (ESRF) but also to 
cardiovascular events (Toto, 2005). Since it is a chronic lifestyle disease, so, the 
principal approaches to retard the progression of kidney deterioration are through 
intensive management of HPT and optimization of BP control. These approaches can 
either be non-pharmacological or pharmacological. Non-pharmacological approaches 
for the management of HPT included the education of patients regarding lifestyle 
modification such as weight reduction, Diet, smoking cessation, Physical activity, 
moderate alcohol consumption, dietary sodium restriction (Martin, 2008). The 
pharmacological approaches for the treatment of HPT include the use of single or 
combination of anti-hypertensive medications. 
 
1.9.2 Diabetes mellitus 
According to Kidney Early Evaluation Program (KEEP), diabetes mellitus (DM) is a 
condition in which fasting blood sugar level is > 7 mmol/L or non-fasting blood 
glucose level ≥ 11 mmol/L (Whaley-Connell et al., 2008). DM is categorized into four 
classes namely type 1 DM (resulting from β cells destruction leading to absolute 
insulin deficiency), type 2 DM (consequence of progressive insulin secretory defect), 
gestational DM and other specific types of DM such as birth defects and chemical 
induced diabetes (American Diabetes Association, 2011).  
 
The prevalence of DM in CKD population of US was 28.0% (Whaley-Connell et al., 
2008) whereas it was 40.8% (Martínez-Castelao et al., 2011) and 62.3% (Al-Ramahi, 
2012) in the Spanish and Malaysian CKD population, respectively. Diabetic 
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nephropathy occurs as a result of the interplay of metabolic and hemodynamic 
pathways in the renal microcirculation (Figure 1.1) (Cooper et al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schema outlining potential interactions between metabolic and hemodynamic factors 
in the pathogenesis of diabetic nephropathy 
 
Adapted from Cooper, Jerums, & Gilbert (1997); TGF=transforming growth factor; VEGF=vascular 
endothelial growth factor; PKC=protein kinase C. 
 
 
Inhibitors of abovementioned pathways have increased the understanding of the 
underlying pathogenic pathways and have led to the development of approaches for 
the treatment of diabetic nephropathy (Mark, 1998). Pathophysiological mechanisms 
and their putative treatment in diabetic nephropathy are presented in Table 1.6. 
Glucose 
Advanced 
glycation end-
products 
Vasoactive hormones 
PKC-βII 
Cytokines 
TGF-β VEGF 
Flow/Pressure 
Metabolic Hemodynamic 
Proteinuria 
Extracellular 
matrix 
accumulation 
↑ Vascular 
permeability 
↑ Extracellular 
matrix 
Extracellular 
matrix cross-
linking 
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Table 1.6: Suggested pathophysiological pathways and their putative treatment 
in diabetic nephropathy 
Mechanism Treatment 
Metabolic 
 Hyperglycemia 
 Increased glucose-derived proteins (e.g. 
AGE) 
  
Polyol 
 
Insulin 
Aminoguanidine 
Advanced glycated endproducts (e.g. 
PTB) 
Aldose reductase inhibitors 
Mechanical/hormonal 
 Elevated systemic blood pressure 
 Increased intraglomerular pressure 
 Increased vasoactive hormones 
 
Antihypertensive agents 
ACE inhibition, low protein diet 
ACE inhibition, angiotensin-II 
antagonists , ET antagonists 
Intermediate pathways 
 Growth factors e.g. TGFβ, IGF 
 Protein kinase C dependent 
 
Antibodies 
PKCβ inhibitors 
 
Adapted from Cooper (1998); AGE-advanced glycated endproducts; ACE-angiotensin converting 
enzyme; IGF-insulin like growth factor; TGF-transforming growth factor; ET-endothelin; PTB-
phenacylthiazolium bromide; PKC-protein kinase C 
 
1.9.3 Cardiovascular disease 
Cardiovascular disease (CVD) is the principal outcome of CKD and the most frequent 
cause of mortality in advance stages of CKD (Levey et al., 2003). Nearly half of the 
overall mortality in CKD patients is associated with CVD (Haynes & Winearls, 
2010). Moreover, cardiovascular mortality in CKD population is 10-20 times greater 
than normotensive population (Foley et al., 1998). The risk rate of cardiovascular 
mortality was 32 deaths/1000 person-years in patients with CKD compared to 
16/1000 person-years among those without CKD (Shlipak et al., 2005). Therefore, 
CKD is considered as a risk factor of CVD. Moreover, anemia, HPT, DM and mineral 
bone disease are also the predictors of CVD (Haynes & Winearls, 2010).  
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1.9.4 Anemia 
 Anemia is defined as serum hemoglobin < 13.0 g/dL in males and < 12 g/dL in 
females (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 
2012). Anemia is a sequela of CKD which occurs as a result of interference of 
erythropoietin (EPO) production responsible to stimulate bone marrow for production 
of red blood cells (Singh et al., 2006). Moreover, other factors such as iron and 
vitamin deficiency, blood loss, decreased life span of erythrocytes, and chronic 
inflammation also play contributory role in the development of renal anemia (Nurko, 
2006). Recent data suggest that anemia is an independent risk factor of adverse 
cardiovascular outcomes (Sarnak et al., 2002) and combination of anemia and CKD 
was associated with significantly higher stroke risk (Abramson et al., 2003). The 
prevalence of anemia is less than 10% in CKD stage 1 and 2, 20-40% in CKD stage 3, 
50-60% in stage 4 CKD and more than 70% in stage 5 CKD which reflects that 
prevalence of anemia increases with declining kidney function (Lankhorst & Wish, 
2010).  
 
1.9.5 Kidney stones 
Kidney stones are the risk factor of CKD as the prevalence of CKD was higher in 
stone formers (6.9%) than normotensive subjects (3.1%) (Rule et al., 2009). A 
previous study surveyed the history of kidney stones in 300 African Americans and 
compared their results with the 5341 African Americans who participated in National 
Health and Nutrition Examination Survey III and found out that the self-reported 
history of kidney stones was higher in ESRD patients (8%) as compared to the 
population controlled subjects (3%) (Stankus et al., 2007). The mechanism through 
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which kidney stones cause CKD is mainly attributed either to an obstructive uropathy 
or pyelonephritis (Rule et al., 2011).  
 
1.9.6 Chronic kidney disease-Mineral and bone disorders (CKD-MBD) 
A progressive worsening in mineral homeostasis occurs when renal function 
decreases, with abnormalities of phosphorus and calcium concentrations, and 
disruptions of hormones levels including parathyroid hormone, 25-hydroxyvitamin D, 
1,25-dihydroxyvitamin D, and other metabolites of vitamin D, fibroblast growth 
factor-23, and growth hormone. Starting from CKD stage 3, kidneys ability to 
eliminate phosphate load is reduced, causing hyperphosphatemia, higher Parathyroid 
hormone, and diminished 1,25-dihydroxyvitamin D with associated increase in 
fibroblast growth factor levels. There is a decreased intestinal absorption of calcium 
and increased parathyroid hormone due to the impaired conversion of 25-
hydroxyvitamin D to 1,25-dihydroxyvitamin D. The kidneys do not respond 
sufficiently to PTH, which promotes the excretion of phosphate and reabsorption of 
calcium (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 
2009). CKD-MBD is defined as a systemic disorder of mineral and bone metabolism 
because of CKD indicated by either one or combination of following (Moe et al., 
2006); 
 
 Abnormalities of calcium, phosphorus, parathyroid hormone levels, or vitamin D 
metabolism 
 Anomalies of bone turnover, mineralization, linear growth, volume, or strength 
 Vascular calcification 
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The abnormalities of calcium, phosphorus and parathyroid hormone are associated 
with vascular calcification and cardiovascular events particularly in patients with 
advanced CKD (Toussaint et al., 2011). 
 
1.9 Consequences of Chronic kidney disease 
Renal failure is traditionally regarded as the most serious outcome of CKD (Levey & 
Coresh, 2012). Other outcomes of CKD are the complications of declined GFR, 
higher risk of CVD, acute renal injury, cognitive impairment, infections and impaired 
physical function (Hailpern et al., 2007; C. Hsu et al., 2008; James et al., 2010; James 
et al., 2009; Wilhelm-Leen et al., 2009). Complications can occur at any stage of 
CKD which often lead to death without progression to kidney failure (Levey & 
Coresh, 2012).   
 
Keith et al., (2004) reported that the rate of RRT over the 5-year (1996-2001) 
observation period was 1.1%, 1.3%, and 19.9%, respectively, for the CKD stages 2, 3, 
and 4, but that the mortality rate was 19.5%, 24.3%, and 45.7%. Thus, death was far 
more common than dialysis at all stages. Go et al., (2004) reported that the risk of 
death increased as the GFR decreased below 60 ml/min/1.73m
2
: the adjusted hazard 
ratio for death was 1.2 with an estimated GFR of 45-59 ml/min/1.73m
2
, 1.8 with 
estimated GFR of 30-44 ml/min/1.73m
2
, 3.2 with an estimated GFR of 15-29 
ml/min/1.73m
2
, and 5.9 with an estimated GFR < 15 ml/min/1.73m
2
. Furthermore, the 
adjusted hazard ratio for cardiovascular events also increased inversely with the 
estimated GFR. 
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Kurella et al., (2004) found that there was a graded relation between cognitive 
function and severity of CKD. Mean scores of Modified Mini-Mental State 
Examination (3MS), Trailmaking Test B (Trails B), and California Verbal Learning 
Trial (CVLT) immediate and delayed recall were worse for ESRD patients than CKD 
patients or published norms (p < 0.001 for all comparisons). Moreover, the scores on 
the Trails B (p < 0.001) and CVLT immediate (p = 0.01) and delayed (p < 0.001) 
recall were significantly worse for subjects with CKD not requiring dialysis than for 
published norms.   
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CHAPTER 2 
LITERATURE REVIEW 
 
This chapter contains the review of literature. Moreover, it also includes rationale and 
aims of the study which are given at the end of this chapter. 
 
2.1 Search strategy  
A literature search was conducted on Google Scholar, PubMed, Science direct and 
ProQuest databases to find all potentially relevant publications before July 2014.  The 
following words were used for current search: “chronic kidney disease”, “chronic 
renal failure”, “end-stage renal disease”, “epidemiology”, “etiology”, “medication 
prescribing patterns”, and “medication related problems”. The reference lists of 
primary original articles and review articles were also checked so that further relevant 
studies could be found. 
 
2.2 Study selection 
Research articles and review articles that reported either the etiologies/causes of CKD 
or medication prescribing patterns among CKD patients were included whereas the 
data published as case reports or in the form of abstracts were excluded due to the 
insufficiency of information in the abstracts. 
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2.3 Demographic patterns of chronic kidney disease 
A prospective study conducted in 4 nephrology centers of US found that the mean age 
of pre-dialysis patients was 60.6 ± 16.0 years (61.3 ± 15.8 years in CKD stage 2 and 
3, 60.8 ± 16.6 years in CKD stage 4 and 59.1 ± 14.1 years in CKD stage 5). 
Moreover, men were more likely to have CKD as compared to female (66% vs 44%) 
and the prevalence of CKD stages 2 and 3, 4 and 5 was 24.2%, 56.5% and 18.7%, 
respectively. The most common comorbidity was hypertension followed by diabetes. 
They suggested increasing the screening programs for the early detection of 
individuals with CKD or risk of CKD development (Bailie et al., 2005). 
 
Martinez-Castelao et al. (2011) conducted a prospective study on Spanish cohort of 
CKD stage 3 and 4 patients. The mean age of their cohort was 68 ± 13 years and there 
was no significant difference of age between CKD stages. Moreover, they observed a 
preponderance of male and overweight patients. They revealed that the prevalence of 
hypertension was universal among CKD stages whereas the prevalence of CVD 
increased significantly by declining renal function with the hierarchy (stage 3a < stage 
3b < stage 4). 
 
Gooneratne et al., (2006) carried out a descriptive hospital-based 3-month study at 
National Hospital of Sri Lanka. They recruited 121 patients with male to female ratio 
being 2.5:1. The mean age of the patients was 47.8 years (range 20-83) and there was 
predominance of Sinhalese (75.2%) and patients from Western province (57%). The 
percentage of patients with CKD stage 3, 4, 5 and acute on chronic kidney disease 
was 3.3%, 4.1%, 66.9% and 5%, respectively. The stage of CKD was unknown or 
undetermined in 20.7% of their cohort. 
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A prospective study conducted in Penang General Hospital, Malaysia revealed that 
the mean age of the patients was 55.56 ± 14.15 years and there was majority of the 
male CKD patients and Chinese race. The prevalence of CKD stage 3, 4 and 5 was 
3.7%, 7.7% and 88.7%, respectively. The common comorbidities were anemia 
(87.3%), hypertension (80.0%) and diabetes mellitus (62.3%) (Al-Ramahi, 2012). 
 
2.4 Trends of known and unknown etiologies of chronic kidney disease 
Etiologies of CKD vary from country to country but diabetes and HPT are the 
foremost etiologies of CKD in all developed and several developing countries while 
glomerulonephritis (GN) and unknown etiology are more frequent causes of CKD in 
Asian and African countries (Jha et al., 2013). These variances are associated to the 
disease burden moving away from infections towards diseases of longevity, reduced 
birth rates, and higher life expectancy in developed nations (Ayodele & Alebiosu, 
2010). On the contrary, infectious diseases (e.g. pyelonephritis, post-streptococcal GN 
etc.) remain to be more prevalent in low economic countries due to poor sanitation, 
insufficient supply of safe water and greater concentrations of disease-transmitting 
vectors (Engelgau, 2011). 
 
According to the United States Renal Data System (2013) report, diabetic 
nephropathy was the leading etiology of ESRD followed by HPT while glomerular 
diseases and adult polycystic kidney disease (APKD) were among the less frequent 
causes. Major known causes of ESRD in New Zealand and Australia were DN (49% 
and 36%, respectively), GN (20% and 19%, respectively), HPT (9% and 12%, 
respectively) while unknown etiology was 3% and 6%, respectively (Grace, 
McDonald, Hurst, & Clayton, 2013). The etiologies of ESRD reported in European 
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and some other countries are depicted in Figure 2.1 (European Renal Association- 
European Dialysis and Transplant Association, 2013). Diabetes and HPT are the 
leading causes of kidney failure in majority of the European nations. The incidence of 
renal failure due to diabetes and hypertension ranged from 12.6-50.0 % and 2.3-30.0 
%, respectively. On the other hand, GN is the foremost etiology of ESRF in Russia, 
Albania and Ukraine. The incidence of kidney failure due to unknown etiology ranged 
from 0-22.9% (Figure 2.1). 
 
 
Figure 2.1 Etiologies of end-stage renal disease in European and some other countries  
 
 
A retrospective study conducted on 182 chronic renal failure (CRF) patients at a 
Nigerian tertiary care institute revealed that chronic glomerulonephritis (CGN) 
(41.2%) was the commonest cause of CRF  followed by hypertensive nephrosclerosis 
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(26.1%) and DN (13.1%) (Alebiosu et al., 2006).  To highlight the burden of CKD, 
another study was carried out in south-east Nigerian tertiary care setting, involving 
1538 ESRD patients which demonstrated that 86.5% of their patients were less than 
60 years old and the cause of ESRD was uncertain in more than half of the patients 
while the leading identifiable causes were HPT and GN accounted in 17.6% and 
14.6% of their study participants (Ulasi & Ijoma, 2010). In another epidemiological 
study involving 800 ESRD Egyptian patients, the known etiologies of ESRD were 
HPT (20%), obstructive uropathy (OBS) (12%), CGN (11%), diabetic nephropathy 
(DN) (8%), chronic pyelonephritis (CPN) (5%), analgesic nephropathy (5%), 
bilhaziasis (3%) and lupus nephritis (9%) while cause of ESRD was unknown in 
majority of their patients (27.1%) (El Minshawy, 2011). 
 
The most frequent cause of CRF in Yemen was GN (25.4%), followed by OBS 
(13.7%), HPT and pyelonephritis (11.8% each), DN (7.8%) and the less frequent 
causes were malaria, arthritis, postpartum hemorrhage, vasculitis, and Alport’s 
syndrome (Badheeb, 2006). According to a study conducted on 248 HD patients in 
Jeddah (Kingdom of Saudi Arabia) to investigate the causes of ESRD found that the 
majority of their ESRD cases were of unknown cause (42.7%) and HPT was the 
commonest identifiable cause followed by DN (Al-Jiffri & Fadag, 2003). Similarly, a 
retrospective medical records review of  1357 ESRD Saudi patients showed that the 
most common known causes of ESRD were HPT (45.9%) followed by DN (17.7%) 
and Glomerular diseases (15.8%) (Maimini et al., 2012). Moreover, the percentage of 
ESRD patients due to unknown cause in the abovementioned study was 1%. On the 
contrary, a prospective study of incident ESRD patients in Madinah (Kingdom of 
Saudi Arabia) indicated that the leading known cause of ESRD was DN (42.5%) and 
